Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SHMP Stock Summary
Top 10 Correlated ETFs
SHMP
In the News
NaturalShrimp to Present at LD Micro Invitational XII Conference on June 7, 2022
Company to Showcase Gourmet-Grade Pacific White Shrimp to LD Micro Invitational XII Attendees
4 Stocks Under $2 Insiders Are Aggressively Buying
US stock futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.
NaturalShrimp to Present at the 14th Annual LD Micro Main Event on October 12, 2021
Company to Showcase Gourmet-Grade Pacific White Shrimp to Conference Attendees During Welcome Reception at Luxe Sunset Boulevard Hotel
NaturalShrimp Announces Initial Validation Study Results of Hyper-Antioxidant Technology for Freshwater Salmon
DALLAS, TX, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today announced initial trial results of its short-term validation study at the Marineholmen RASLab, in Bergen Norway, to evaluate the effects of hyper-antioxidant technologies on oxidation and fish health in Recirculating Aquaculture Systems (RAS).
NaturalShrimp Launches Next-Generation Investor Website
DALLAS, TX, Sept. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), announced the debut of its new investor relations website .
NaturalShrimp Closes Acquisition of Hydrenesis Aquaculture, LLC
DALLAS, TX, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today closed the previously announced acquisition of the aquaculture assets of Hydrenesis Aquaculture, LLC for $12,500,000, consisting of $4,000,000 in cash and the balance due in NSI common stock, including a stock consideration payment at a price of $0.505 per share.
NaturalShrimp Hires Industry Veteran Marco Van Den Berg to Lead Sales and Marketing
DALLAS, TX, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), today announced the appointment of Marco Van Den Berg to lead the Company's sales and marketing activities, with responsibility for business in North America. Marco will initially act in a consulting capacity before transitioning to the position of Vice President of Sales.
NaturalShrimp Files New Patent Application to Expand Its Electrocoagulation Technology
Patent Application Incorporates New Novel Improvements to Recirculating Aquaculture System and Treatment Method for Aquatic Species
NaturalShrimp Accelerates Growth with Opening of New Corporate Headquarters in Dallas, Texas
New Office Expansion Enables NaturalShrimp to Accelerate Growth in Sales & Marketing with State-of-the-Art Test Kitchen & Dining Area
NaturalShrimp, Inc. Closes $3,000,000 Registered Direct Offering
Dallas, Texas, June 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), announced today that it has closed a registered direct offering of 7,500,000 shares of the Company's common stock for gross proceeds of $3,000,000 pursuant to an effective shelf registration statement on Form S-3. The investor purchased the shares at a fixed price of $0.40 per share. This brings the total raised under the S-3 to $18M at an average price of $.525/share.
SHMP Financial details
SHMP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.04 | -0.02 | -0.01 | -0.18 | -0.01 | |
Operating cash flow per share | -0.01 | -0.01 | 0 | -0.02 | -0.01 | |
Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.03 | -0.01 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -0.02 | -0.01 | 0.01 | 0.02 | 0 | |
Tangible book value per share | -0.02 | -0.01 | 0.01 | -0.01 | -0.02 | |
Share holders equity per share | -0.02 | -0.01 | 0.01 | 0.02 | 0 | |
Interest debt per share | 0.02 | 0.01 | 0.02 | 0.01 | 0.03 | |
Market cap | 33.75M | 11.41M | 268.19M | 139.36M | 47.29M | |
Enterprise value | 36.49M | 13.6M | 276.15M | 141.28M | 72.43M | |
P/E ratio | -4.68 | -2.32 | -72 | -1.23 | -4.68 | |
Price to sales ratio | 0 | 0 | 0 | 4.13K | 198.14 | |
POCF ratio | -34.08 | -4.59 | -112.81 | -11.08 | -8.07 | |
PFCF ratio | -28.08 | -3.07 | -45.98 | -6.97 | -5.63 | |
P/B Ratio | -11.81 | -3.99 | 51.75 | 10.71 | -642.49 | |
PTB ratio | -11.81 | -3.99 | 51.75 | 10.71 | -642.49 | |
EV to sales | 0 | 0 | 0 | 4.18K | 303.47 | |
Enterprise value over EBITDA | -8.14 | -4.84 | -90.05 | -2.61 | -6.45 | |
EV to operating cash flow | -36.84 | -5.48 | -116.16 | -11.23 | -12.36 | |
EV to free cash flow | -30.35 | -3.66 | -47.35 | -7.06 | -8.62 | |
Earnings yield | -0.21 | -0.43 | -0.01 | -0.81 | -0.21 | |
Free cash flow yield | -0.04 | -0.33 | -0.02 | -0.14 | -0.18 | |
Debt to equity | -1.01 | -0.81 | 1.57 | 0.28 | -344.5 | |
Debt to assets | 1.65 | 0.99 | 0.53 | 0.1 | 0.78 | |
Net debt to EBITDA | -0.61 | -0.78 | -2.6 | -0.04 | -2.24 | |
Current ratio | 0.05 | 0.24 | 0.18 | 0.22 | 0.17 | |
Interest coverage | -4.48 | -11.75 | -22.89 | -16.29 | -1.54 | |
Income quality | 0.14 | 0.53 | 0.66 | 0.15 | 0.37 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 1.48K | 24.82 | |
Research and developement to revenue | 0 | 0 | 0 | 12.08 | 0.8 | |
Intangibles to total assets | 0 | 0 | 0 | 0.45 | 0.47 | |
Capex to operating cash flow | 0.21 | 0.5 | 1.45 | 0.59 | 0.43 | |
Capex to revenue | 0 | 0 | 0 | -220.12 | -10.68 | |
Capex to depreciation | -6.99 | -12.28 | -9.97 | -3.4 | -0.76 | |
Stock based compensation to revenue | 0 | 0 | 0 | 1.31K | 0.42 | |
Graham number | 0.13 | 0.05 | 0.04 | 0.29 | 0 | |
ROIC | -11.46 | 7.68 | -0.25 | -4.2 | -0.28 | |
Return on tangible assets | -4.13 | -2.12 | -0.24 | -5.37 | -0.59 | |
Graham Net | -0.03 | -0.02 | -0.02 | -0.04 | -0.03 | |
Working capital | -3.77M | -3.6M | -3.61M | -17.02M | -9.34M | |
Tangible asset value | -2.86M | -2.94M | 5.09M | -3.86M | -15.48M | |
Net current asset value | -4.42M | -4.1M | -9.31M | -20.05M | -30.78M | |
Invested capital | -1.01 | -0.81 | 1.57 | 0.28 | -344.5 | |
Average receivables | 104.45K | 850 | 0 | 7.19K | 15.86K | |
Average payables | 552.28K | 608.59K | 802.22K | 1.88M | 3.16M | |
Average inventory | 2.1K | 2.1K | 0 | 34.59K | 47.45K | |
Days sales outstanding | 0 | 0 | 0 | 155.5 | 26.49 | |
Days payables outstanding | 850.99 | 2.33K | 1.01K | 0 | 6.38K | |
Days of inventory on hand | 6.2 | 0 | 0 | 0 | 46.75 | |
Receivables turnover | 0 | 0 | 0 | 2.35 | 13.78 | |
Payables turnover | 0.43 | 0.16 | 0.36 | 0 | 0.06 | |
Inventory turnover | 58.83 | 0 | 0 | 0 | 7.81 | |
ROE | 2.52 | 1.72 | -0.72 | -8.67 | 137.15 | |
Capex per share | 0 | 0 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.01 | 0 | 0 | 0 | -0.01 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | -0.01 | |
Tangible book value per share | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | |
Share holders equity per share | 0 | 0 | 0 | 0 | -0.01 | |
Interest debt per share | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
Market cap | 128.72M | 47.29M | 33.09M | 21.5M | 11.07M | |
Enterprise value | 152.16M | 72.43M | 59.22M | 47.25M | 39.72M | |
P/E ratio | 2.12 | -3.03 | -3.6 | -2.03 | -0.51 | |
Price to sales ratio | 1.31K | 897.71 | 160.71 | 370.59 | 109.29 | |
POCF ratio | -506.23 | -23.96 | -23.62 | -26.89 | -16.89 | |
PFCF ratio | -51.99 | -22.6 | -22.97 | -26.57 | -16.42 | |
P/B Ratio | 47.22 | -642.49 | -38.96 | -7.29 | -1.6 | |
PTB ratio | 47.22 | -642.49 | -38.96 | -7.29 | -1.6 | |
EV to sales | 1.55K | 1.37K | 287.66 | 814.59 | 392.08 | |
Enterprise value over EBITDA | -39.35 | -20.84 | -38.89 | -23.35 | -30.34 | |
EV to operating cash flow | -598.42 | -36.7 | -42.27 | -59.1 | -60.61 | |
EV to free cash flow | -61.46 | -34.62 | -41.12 | -58.41 | -58.92 | |
Earnings yield | 0.12 | -0.08 | -0.07 | -0.12 | -0.49 | |
Free cash flow yield | -0.02 | -0.04 | -0.04 | -0.04 | -0.06 | |
Debt to equity | 8.65 | -344.5 | -30.86 | -8.75 | -4.14 | |
Debt to assets | 0.73 | 0.78 | 0.83 | 0.88 | 1.01 | |
Net debt to EBITDA | -6.06 | -7.23 | -17.16 | -12.73 | -21.88 | |
Current ratio | 0.1 | 0.17 | 0.17 | 0.03 | 0.03 | |
Interest coverage | -2.12 | -4.41 | -256.93 | -69.98 | -82.18 | |
Income quality | -0.02 | 0.45 | 0.61 | 0.3 | 0.12 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 15.12 | 31.64 | 6.31 | 41.44 | 0 | |
Research and developement to revenue | 0.15 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.49 | 0.47 | 0.47 | 0.5 | 0 | |
Capex to operating cash flow | 8.74 | 0.06 | 0.03 | 0.01 | 0.03 | |
Capex to revenue | -22.68 | -2.24 | -0.19 | -0.16 | -0.19 | |
Capex to depreciation | -2.83 | -0.13 | -0.05 | -0.01 | -0.02 | |
Stock based compensation to revenue | 0.25 | 0 | 0.02 | 0 | 0 | |
Graham number | 0.02 | 0 | 0.01 | 0.02 | 0.03 | |
ROIC | -0.11 | -0.09 | -0.09 | -0.18 | -0.1 | |
Return on tangible assets | 0.92 | -0.23 | -0.14 | -0.18 | -0.19 | |
Graham Net | -0.02 | -0.03 | -0.04 | -0.04 | -0.04 | |
Working capital | -8.19M | -9.34M | -8.78M | -10.26M | -10.41M | |
Tangible asset value | -13.05M | -15.48M | -15.89M | -17.62M | -6.93M | |
Net current asset value | -28.69M | -30.78M | -30.76M | -32.03M | -35.11M | |
Invested capital | 8.65 | -344.5 | -30.86 | -8.75 | -4.14 | |
Average receivables | 39.81K | 12.41K | 26.83K | 19.21K | 9.21K | |
Average payables | 3.35M | 3.52M | 3.53M | 3.61M | 3.68M | |
Average inventory | 105.59K | 63.83K | 36.19K | 43.36K | 39.36K | |
Days sales outstanding | 6.89 | 29.6 | 15.88 | 3.25 | 14.5 | |
Days payables outstanding | 404.51 | 858.23 | 6.41K | 6.49K | 331.89 | |
Days of inventory on hand | 11.7 | 6.29 | 84.42 | 70.69 | 3.49 | |
Receivables turnover | 13.06 | 3.04 | 5.67 | 27.68 | 6.21 | |
Payables turnover | 0.22 | 0.1 | 0.01 | 0.01 | 0.27 | |
Inventory turnover | 7.69 | 14.31 | 1.07 | 1.27 | 25.8 | |
ROE | 5.57 | 52.96 | 2.71 | 0.9 | 0.78 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SHMP Frequently Asked Questions
What is NaturalShrimp Incorporated stock symbol ?
NaturalShrimp Incorporated is a US stock , located in Dallas of Tx and trading under the symbol SHMP
What is NaturalShrimp Incorporated stock quote today ?
NaturalShrimp Incorporated stock price is $0.0112 today.
Is NaturalShrimp Incorporated stock public?
Yes, NaturalShrimp Incorporated is a publicly traded company.